Last reviewed · How we verify
MVA-BN standard regimen
MVA-BN is a live attenuated vaccinia virus-based vaccine that stimulates immune responses against monkeypox virus antigens.
MVA-BN is a live attenuated vaccinia virus-based vaccine that stimulates immune responses against monkeypox virus antigens. Used for Monkeypox prevention in at-risk populations, Post-exposure prophylaxis for monkeypox.
At a glance
| Generic name | MVA-BN standard regimen |
|---|---|
| Sponsor | Jean-Pierre Van geertruyden |
| Drug class | Live attenuated viral vaccine |
| Target | Monkeypox virus antigens |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
MVA-BN (Modified Vaccinia Ankara-Bavarian Nordic) is a replication-competent orthopoxvirus vaccine derived from vaccinia virus. It expresses immunogenic proteins from monkeypox virus to elicit both cellular and humoral immune responses. The vaccine is designed to provide protection against monkeypox infection through activation of T-cell and B-cell mediated immunity.
Approved indications
- Monkeypox prevention in at-risk populations
- Post-exposure prophylaxis for monkeypox
Common side effects
- Injection site reactions (erythema, swelling, pain)
- Myalgia
- Fatigue
- Headache
- Fever
Key clinical trials
- Phase 3 Maternal Safety & Immunogenicity Trial of MVA-BN® in DRC (PHASE3)
- Open-label, Multicenter Immunogenicity and Safety Study of MVA-BN Vaccine in Children From 2 Years to Less Than 12 Years of Age Compared to Adults for the Prevention of Smallpox, Mpox, and Related Orthopoxvirus Infections (PHASE2)
- Phase 3 Infant Safety & Immunogenicity Trial of MVA-BN® in DRC (PHASE3)
- Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection (PHASE2)
- Combination Study With MVA BN and Dryvax (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MVA-BN standard regimen CI brief — competitive landscape report
- MVA-BN standard regimen updates RSS · CI watch RSS
- Jean-Pierre Van geertruyden portfolio CI